PegIntron or Pegasys 2009

Back to Main Page

Research on Pegasys and PegIntron

2008

Click here for :2007-2004

July-June

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin

July 09

Ribavirin Prevents Relapse

Early EPO Use Increased SVR Rates and Reduced Discontinuation Rate !

EXTENDED TREATMENT DURATION TO 72 Weeks IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY (SUCCESS) -

Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C

HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans

Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
 

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response

May

ALT Level Increase Common During HCV Therapy
www.medscape.com

NEW YORK (Reuters Health) May 21 - Elevations in alanine aminotransferase (ALT) levels late in the course of antiviral therapy of hepatitis C virus (HCV) RNA-negative patients are not unusual and may be associated with virological relapse in some cases, Italian researchers report in the May issue of Hepatology.

However, senior investigator Dr. Antonino Picciotto told Reuters Health: "Elevated ALT in HCV RNA-negative patients during pegylated interferon and ribavirin therapy should not be a reason for treatment discontinuation."

Dr. Picciotto of the University of Genoa and colleagues studied 173 chronic hepatitis C patients who achieved viral clearance during combination therapy.

Overall, 33% of the patients with undetectable HCV RNA had elevated ALT in at least one scheduled visit during a 24-week follow-up period; included were patients with HCV genotype 1 or 4 who alone were followed for 48 weeks.

The distribution of these findings did not differ between sustained responders and those who responded and then relapsed. The researchers found no association with pretreatment demographic features, such as age and gender, or with clinical or viral parameters.

However, at 12 weeks until the end of treatment, elevated ALT was more common in relapsed responders (90%) than in those who maintained a sustained response (9%).

Dr. Picciotto concludes that elevated ALT "during the late phase of therapy may suggest a higher risk of relapse."

Hepatology 2009;49:1442-1448

IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response

FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C

Hepatitis C Treatment Is More Successful before Progression to Advanced Liver Damage

Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients

EASL: Albuferon vs Pegasys Genotype 1 - (05/06/09)

Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy

Re-Treatment With Pegasys(R) Provides Hepatitis C Patients With A Second Chance For A Cure, Switzerland, New Study

Summaries For Patients: Re-treating Patients With Chronic Hepatitis C Who Have Not Responded to Peginterferon-2b

Early treatment gives hepatitis C patients the all-clear

Taribavirin vs Ribavirin -

EASL: PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial

EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients -

SL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus

EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients - (04/30/09)

EASL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09)

EASL: Antiviral activity and safety of TMC435 combined with peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy - (04/29/09) 

EASL: Antiviral Activity of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients Chronically Infected with HCV Genotype 1 - (04/29/09)

EASL: Can Peginterferon and Ribavirin Be Eliminated from Therapy -

EASL: Peg-Interferon lambda + Ribavirin 4 Weeks - (04/28/09)

April-March

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-{alpha}2b 04-22

FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment

Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection -

Racial Differences in Response to Interferon-Based Antiviral Therapy for Hepatitis C Virus Infection: A Hardwiring Issue? EDITORIAL COMMENTARY

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients - "No patient had conclusive evidence of virologic relapse" -

Combination therapy eases fibromyalgia symptoms

Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b

February-January

Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response

New Genetic Test May Help Predict Response to Hepatitis C Treatment

LATINO Study Comments by Jules Levin -

PEGASYS Proven Effective as Hepatitis C Treatment for Latino Patients -

Pegylated interferon -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy

Using Math To Understand Hep. C: Patterns Paint Picture Of Who Will Respond To Treatment

A Randomized Study of Extended Treatment With Peginterferon alpha-2b Plus Ribavirin Based on Time to HCV RNA Negative-Status in Patients With Genotype 1b Chronic Hepatitis C

Pegasys Maintenance in HALT-C